AVXL · Anavex Life Sciences Corp.

The departure of Felix Lauscher as COO after a brief tenure of about 2.5 months signals internal restructuring at Anavex Life Sciences, triggered by the recent appointment of Dr. Terrie Kellmeyer as Interim CEO. This reorganization of duties may aim to streamline operations or align leadership with strategic priorities. Lauscher's compensation package included a modest base salary of $264,000 annually, reflecting the biotech firm's cost-conscious approach, with limited equity retention post-departure (only 4,167 options exercisable briefly at $4.69). The severance offer of two weeks' pay underscores standard exit terms without significant ongoing liabilities for investors.